Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, Lee R, Tatevossian RG, Phoenix TN, Thiruvenkatam R, White E, Tang B, Orisme W, Gupta K, Rusch M, Chen X, Li Y, Nagahawhatte P, Hedlund E, Finkelstein D, Wu G, Shurtleff S, Easton J, Boggs K, Yergeau D, Vadodaria B, Mulder HL, Becksfort J, Gupta P, Huether R, Ma J, Song G, Gajjar A, Merchant T, Boop F, Smith AA, Ding L, Lu C, Ochoa K, Zhao D, Fulton RS, Fulton LL, Mardis ER, Wilson RK, Downing JR, Green DR, Zhang J, Ellison DW, Gilbertson RJ.

Nature. 2014 Feb 27;506(7489):451-5. doi: 10.1038/nature13109. Epub 2014 Feb 19. Erratum in: Nature. 2014 Apr 24;508(7497):554. Becksford, Jared [corrected to Becksfort, Jared].

2.

Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF-κB signaling pathway.

Pietsch T, Wohlers I, Goschzik T, Dreschmann V, Denkhaus D, Dörner E, Rahmann S, Klein-Hitpass L.

Acta Neuropathol. 2014 Apr;127(4):609-11. doi: 10.1007/s00401-014-1264-4. Epub 2014 Feb 22. No abstract available.

PMID:
24562983
3.

C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.

Cachia D, Wani K, Penas-Prado M, Olar A, McCutcheon IE, Benjamin RS, Armstrong TS, Gilbert MR, Aldape KD.

Brain Tumor Pathol. 2015 Apr;32(2):105-11. doi: 10.1007/s10014-014-0205-1. Epub 2014 Nov 12.

4.

C11orf95-RELA fusion present in a primary intracranial extra-axial ependymoma: Report of a case with literature review.

Nambirajan A, Malgulwar PB, Sharma MC, Singh A, Pathak P, Satyarthee GD, Garg A.

Neuropathology. 2016 Oct;36(5):490-495. doi: 10.1111/neup.12299. Epub 2016 Apr 28. Review.

PMID:
27121356
5.

Analysis of the RelA:CBP/p300 interaction reveals its involvement in NF-κB-driven transcription.

Mukherjee SP, Behar M, Birnbaum HA, Hoffmann A, Wright PE, Ghosh G.

PLoS Biol. 2013 Sep;11(9):e1001647. doi: 10.1371/journal.pbio.1001647. Epub 2013 Sep 3.

6.

Cancer: Tumours outside the mutation box.

Versteeg R.

Nature. 2014 Feb 27;506(7489):438-9. doi: 10.1038/nature13061. Epub 2014 Feb 19. No abstract available.

PMID:
24553138
7.

Dishevelled interacts with p65 and acts as a repressor of NF-κB-mediated transcription.

Deng N, Ye Y, Wang W, Li L.

Cell Res. 2010 Oct;20(10):1117-27. doi: 10.1038/cr.2010.108. Epub 2010 Jul 13.

PMID:
20628365
8.

Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.

Nobusawa S, Hirato J, Yokoo H.

Brain Tumor Pathol. 2014 Oct;31(4):229-33. doi: 10.1007/s10014-014-0200-6. Epub 2014 Sep 3. Review.

PMID:
25182241
9.

A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.

Noels H, van Loo G, Hagens S, Broeckx V, Beyaert R, Marynen P, Baens M.

J Biol Chem. 2007 Apr 6;282(14):10180-9. Epub 2007 Feb 7.

10.

Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.

Bassères DS, Ebbs A, Levantini E, Baldwin AS.

Cancer Res. 2010 May 1;70(9):3537-46. doi: 10.1158/0008-5472.CAN-09-4290. Epub 2010 Apr 20.

11.

Interleukin-2 induces NF-kappaB activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells.

Chan KK, Shen L, Au WY, Yuen HF, Wong KY, Guo T, Wong ML, Shimizu N, Tsuchiyama J, Kwong YL, Liang RH, Srivastava G.

J Pathol. 2010 Jun;221(2):164-74. doi: 10.1002/path.2699.

PMID:
20235165
12.

Association of HTLV Tax proteins with TAK1-binding protein 2 and RelA in calreticulin-containing cytoplasmic structures participates in Tax-mediated NF-κB activation.

Avesani F, Romanelli MG, Turci M, Di Gennaro G, Sampaio C, Bidoia C, Bertazzoni U, Bex F.

Virology. 2010 Dec 5;408(1):39-48. doi: 10.1016/j.virol.2010.08.023. Epub 2010 Sep 27.

13.

Methodology to study NF-κB/RelA ubiquitination in vivo.

Li H, Starokadomskyy P, Burstein E.

Methods Mol Biol. 2015;1280:371-81. doi: 10.1007/978-1-4939-2422-6_22.

PMID:
25736761
14.

APPL1 regulates basal NF-κB activity by stabilizing NIK.

Hupalowska A, Pyrzynska B, Miaczynska M.

J Cell Sci. 2012 Sep 1;125(Pt 17):4090-102. doi: 10.1242/jcs.105171. Epub 2012 Jun 8.

15.

Cyclophilin A (CypA) interacts with NF-κB subunit, p65/RelA, and contributes to NF-κB activation signaling.

Sun S, Guo M, Zhang JB, Ha A, Yokoyama KK, Chiu RH.

PLoS One. 2014 Aug 12;9(8):e96211. doi: 10.1371/journal.pone.0096211. eCollection 2014.

17.

Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr.

J Biol Chem. 1997 Sep 26;272(39):24113-6.

18.
19.

EphB2 activation is required for ependymoma development as well as inhibits differentiation and promotes proliferation of the transformed cell.

Chen P, Rossi N, Priddy S, Pierson CR, Studebaker AW, Johnson RA.

Sci Rep. 2015 Mar 24;5:9248. doi: 10.1038/srep09248.

20.

Reprogramming RelA.

Campbell KJ, Perkins ND.

Cell Cycle. 2004 Jul;3(7):869-72. Epub 2004 Jul 4. Review.

PMID:
15190199

Supplemental Content

Support Center